Industry Lunch Symposium: HER2-positive early breast cancer: Determining adjuvant treatment following neoadjuvant therapy
Supported by Genentech
Friday, September 6, 2019
12:45-13:45
Hall B
HER2-positive early breast cancer: Determining adjuvant treatment following neoadjuvant therapy Francis Arena, USA |